FATE THERAPEUTICS INC
FATENASDAQTrading Snapshot
- Day Range
- $2.69 – $2.73
- 52-Week Range
- $0.92 – $3.23
- Volume
- $2.01B
- Avg Volume
- $2.10B
- Shares Outstanding
- 116.6M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $1M
- P/E Ratio
- -2.5
- P/S Ratio
- 50.6x
- EPS (TTM)
- $-1.08
- Dividend Yield
- 0.00%
Why Investors Own FATE
- ✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About FATE THERAPEUTICS INC
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
